Zobrazeno 1 - 7
of 7
pro vyhledávání: '"C J Maurath"'
Autor:
Jay L. Goldstein, J Kaiser, C J Maurath, Naurang M. Agrawal, Kenneth M. Verburg, Richard C. Hubbard, G S Geis, Fred E. Silverstein
Publikováno v:
American Journal of Gastroenterology. 95:1681-1690
The aim of this study was to assess the rate of upper gastrointestinal (UGI) ulcer complications (bleeding, perforation, or gastric outlet obstruction) associated with celecoxib, a specific COX-2 inhibitor, compared with the rate associated with nons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9837532df46f3d930d99c04b2169a2
https://doi.org/10.1111/j.1572-0241.2000.02194.x
https://doi.org/10.1111/j.1572-0241.2000.02194.x
Publikováno v:
American Journal of Therapeutics. 7:159-174
The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Conventional treatment for these debilitating conditions routinely involves the use of conventional
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81747a11fe8f642a840990cbf966c0cc
https://doi.org/10.1097/00045391-200007030-00004
https://doi.org/10.1097/00045391-200007030-00004
Publikováno v:
American journal of therapeutics. 7(3)
Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Many agents used for treating these diseases, both symptom-modifying and disease-modifying, are associat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d380e5c6988396aae9c005619d982276
https://pubmed.ncbi.nlm.nih.gov/11317163
https://pubmed.ncbi.nlm.nih.gov/11317163
Autor:
W G, Bensen, S Z, Zhao, T A, Burke, R A, Zabinski, R W, Makuch, C J, Maurath, N M, Agrawal, G S, Geis
Publikováno v:
The Journal of rheumatology. 27(8)
To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA).An analysis of 5, 12-week, randomized, double blind, parallel group, placebo controlled c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f44775d1723f9070c3de3864a4d36708
https://pubmed.ncbi.nlm.nih.gov/10955327
https://pubmed.ncbi.nlm.nih.gov/10955327
Publikováno v:
Journal of clinical pharmacology. 32(5)
Selected adverse events were evaluated from the combined randomized placebo-controlled clinical trials (once-a-day or twice-a-day; monotherapy or combination therapy) of terazosin in hypertensive patients. The designs of these clinical trials were ei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::519b370492154578b4339a349b14eb2b
https://pubmed.ncbi.nlm.nih.gov/1587961
https://pubmed.ncbi.nlm.nih.gov/1587961
Publikováno v:
Journal of human hypertension. 4(2)
The effects of terazosin, a new, selective, alpha 1-adrenoceptor antagonist, on the serum lipid levels were examined in 103 black patients with uncomplicated, mild to moderate essential hypertension in six randomized, double-blind, placebo-controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::68cfedccd0df35aa1b40ce0544bdf285
https://pubmed.ncbi.nlm.nih.gov/1971028
https://pubmed.ncbi.nlm.nih.gov/1971028
Publikováno v:
Journal of human hypertension. 4(2)
The antihypertensive effects of the selective alpha 1-adrenoceptor antagonist, terazosin, in black patients with uncomplicated, mild to moderate essential hypertension were examined retrospectively in seven randomized, double-blind, placebo-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c0e12799c1df9e4f7a843719e0f2d01a
https://pubmed.ncbi.nlm.nih.gov/1971027
https://pubmed.ncbi.nlm.nih.gov/1971027